ATE345350T1 - Makrolidantibiotika - Google Patents

Makrolidantibiotika

Info

Publication number
ATE345350T1
ATE345350T1 AT01271380T AT01271380T ATE345350T1 AT E345350 T1 ATE345350 T1 AT E345350T1 AT 01271380 T AT01271380 T AT 01271380T AT 01271380 T AT01271380 T AT 01271380T AT E345350 T1 ATE345350 T1 AT E345350T1
Authority
AT
Austria
Prior art keywords
macrolide antibiotic
macrolide
antibiotic
Prior art date
Application number
AT01271380T
Other languages
English (en)
Inventor
Daniele Andreotti
Luca Arista
Stefano Biondi
Francesca Cardullo
Frederica Damiani
Sergio Lociuro
Carla Marchioro
Giancarlo Merlo
Anna Mingardi
Daniela Niccolai
Alfredo Paio
Elisabetta Piga
Alfonso Pozzan
Catia Seri
Luca Tarsi
Silvia Terreni
Jessica Tibasco
Manuela Ciraco
Original Assignee
Glaxo Group Ltd
Pliva D D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0031309A external-priority patent/GB0031309D0/en
Priority claimed from GB0126277A external-priority patent/GB0126277D0/en
Priority claimed from GB0126276A external-priority patent/GB0126276D0/en
Application filed by Glaxo Group Ltd, Pliva D D filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE345350T1 publication Critical patent/ATE345350T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT01271380T 2000-12-21 2001-12-20 Makrolidantibiotika ATE345350T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0031309A GB0031309D0 (en) 2000-12-21 2000-12-21 Macrolides
GB0126277A GB0126277D0 (en) 2001-11-01 2001-11-01 Macrolides
GB0126276A GB0126276D0 (en) 2001-11-01 2001-11-01 Macolides

Publications (1)

Publication Number Publication Date
ATE345350T1 true ATE345350T1 (de) 2006-12-15

Family

ID=27256023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01271380T ATE345350T1 (de) 2000-12-21 2001-12-20 Makrolidantibiotika

Country Status (20)

Country Link
US (3) US20040077557A1 (de)
EP (1) EP1363925B8 (de)
JP (1) JP2004531471A (de)
KR (1) KR20030068189A (de)
CN (1) CN1492874A (de)
AR (1) AR042583A1 (de)
AT (1) ATE345350T1 (de)
AU (2) AU2002217277B2 (de)
BR (1) BR0116431A (de)
CA (1) CA2432429A1 (de)
CZ (1) CZ20031751A3 (de)
DE (1) DE60124594T2 (de)
ES (1) ES2275621T3 (de)
HU (1) HUP0302526A2 (de)
IL (1) IL156561A0 (de)
MX (1) MXPA03005668A (de)
NO (1) NO20032846L (de)
NZ (1) NZ526450A (de)
PL (1) PL365012A1 (de)
WO (1) WO2002050091A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
US6995143B2 (en) * 2002-02-28 2006-02-07 Basilea Pharmaceutica Ag Macrolides with antibacterial activity
US6727229B2 (en) 2002-08-19 2004-04-27 Enanta Pharmaceuticals, Inc. 11,12-substituted lactone ketolide derivatives having antibacterial activity
US6720308B1 (en) 2002-11-07 2004-04-13 Enanta Pharmaceuticals, Inc. Anhydrolide derivatives having antibacterial activity
HRP20020886A2 (en) * 2002-11-11 2005-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. SUBSTITUTED 9a-N-[N'-(BENZENSULFONYL)CARBAMOYL-γ-AMINOPROPYL) AND 9a-N(N' -(?-CYANOETHIL)-N' -(b
HRP20020991A2 (en) * 2002-12-12 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. N"-Substituted 9a-N-(N'-carbamoyl-Gamma-aminopropyl), 9a-N-(N'? -thiocarbamoyl-Gamma-aminopropyl), 9a-N-(N'-((Beta-cyanoethyl)-N'-carbamoyl-Gamma? -aminopropyl) and 9a-N-(N'-(Beta-cyanoethyl)-N'-thiocarbamoyl-Gamma? -aminopropyl) derivatives of 9-de
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
US6774115B1 (en) 2003-06-05 2004-08-10 Enanta Pharmaceuticals, Inc. 6-O-substituted bicyclic ketolides
US6716820B1 (en) 2003-06-05 2004-04-06 Enanta Pharmaceuticals, Inc. 6-O-substituted bicyclic macrolides
US6790835B1 (en) 2003-06-05 2004-09-14 Enanta Pharmaceuticals, Inc. Bicyclic macrolide derivatives
US6765016B1 (en) 2003-06-05 2004-07-20 Enanta Pharmaceuticals, Inc. Bicyclic ketolide derivatives
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
CA2533824A1 (en) * 2003-07-31 2005-02-10 Irm, Llc Bicyclic compounds and compositions as pdf inhibitors
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CN100398536C (zh) * 2003-08-20 2008-07-02 爱密斯菲尔科技公司 用于口服传递glp-1化合物或mc4激动剂肽的化合物、方法和制剂
RU2403237C2 (ru) * 2004-05-14 2010-11-10 Эмисфире Текнолоджис, Инк. Составы и смеси для доставки активных агентов
EP2233493A1 (de) 2004-12-21 2010-09-29 Pfizer Products Inc. Makrolide
CN101115764B (zh) * 2005-02-09 2012-09-26 巴斯利尔药物股份公司 大环内酯类化合物
WO2006120541A1 (en) 2005-05-10 2006-11-16 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Ether linked macrolides useful for the treatment of microbial infections
CN101442996B (zh) * 2006-03-10 2012-04-25 土田裕三 抗微生物剂以及抗微生物组合物
EP2077271A4 (de) * 2006-05-01 2010-09-15 Taisho Pharmaceutical Co Ltd Makrolitderivat
RU2009110254A (ru) 2006-08-24 2010-09-27 Новартис АГ (CH) Производные 2-(пиразин-2-ил)тиазола и 2-(1н-пиразол-3-ил)тиразола и связанные с ним соединения в качестве ингибиторов стеароил-соа десатуразы для лечения метаболических, сердечно-сосудистых и других нарушений
EP2056844A4 (de) * 2006-08-24 2010-11-24 Wockhardt Research Center Neue makrolide und ketolide mit antimikrobieller wirkung
CN101516877B (zh) 2006-09-22 2013-09-11 诺瓦提斯公司 杂环有机化合物
EP2121671A1 (de) 2006-12-20 2009-11-25 Novartis AG 2-substituierte fünfgliedrige heterocyclen als scd-hemmer
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2010025436A2 (en) * 2008-08-29 2010-03-04 Triad Multitech Pharmaceuticals, Inc. Nitrogen and sulfur-containing heterocycle derivatives
RU2011153353A (ru) * 2009-05-27 2013-07-10 Вокхардт Рисерч Сентер Кетолидные соединения, обладающие противомикробной активностью
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
CN102417530A (zh) * 2010-09-26 2012-04-18 中国医学科学院药物研究所 广谱抗菌素红霉素a大环酮内酯类衍生物的合成方法和用途
EP3216798A3 (de) * 2010-12-09 2017-10-25 Wockhardt Limited Ketolidverbindungen
US9206214B2 (en) 2011-03-01 2015-12-08 Wockhardt Ltd. Process for preparation of ketolide intermediates
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20160061743A (ko) 2014-11-24 2016-06-01 주식회사 엘지화학 고흡수성 수지 및 이의 제조 방법
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN110272417B (zh) * 2019-06-18 2021-07-13 五邑大学 2-甲基-1,8-萘啶类化合物及其制备方法与应用
CN115151540A (zh) 2019-12-02 2022-10-04 风暴治疗有限公司 作为mettl3抑制剂的多杂环化合物
US11999703B1 (en) 2023-10-25 2024-06-04 King Faisal University 5-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732684B1 (fr) * 1995-04-06 1997-04-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2742757B1 (fr) * 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ZA989835B (en) * 1997-10-29 1999-05-05 Taisho Pharmaceutical Co Ltd Erythromycin a derivatives
WO1999021870A1 (en) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Erythromycin a 11, 12-carbamate derivatives
AP2001002222A0 (en) * 1999-01-27 2001-09-30 Pfizer Prod Inc Ketolide antibiotics.
US6355620B1 (en) * 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
EP1114826A3 (de) * 1999-12-29 2001-10-31 Pfizer Products Inc. Antibakterielle und prokinetische Makroliden
EP1313751B1 (de) * 2000-08-22 2008-09-17 Basilea Pharmaceutica AG Neue macrolide mit antibakterieller wirkung
CN1589277A (zh) * 2001-09-17 2005-03-02 奥索-麦克尼尔药品公司 6－o－氨基甲酸酯－11,12－内酯－酮内酯抗菌剂

Also Published As

Publication number Publication date
AU2002217277B2 (en) 2005-06-16
DE60124594D1 (de) 2006-12-28
MXPA03005668A (es) 2004-12-03
WO2002050091A1 (en) 2002-06-27
AR042583A1 (es) 2005-06-29
NO20032846L (no) 2003-08-20
NO20032846D0 (no) 2003-06-20
US20040077557A1 (en) 2004-04-22
IL156561A0 (en) 2004-01-04
CA2432429A1 (en) 2002-06-27
EP1363925A1 (de) 2003-11-26
US20050215495A1 (en) 2005-09-29
NZ526450A (en) 2005-04-29
BR0116431A (pt) 2004-06-22
CN1492874A (zh) 2004-04-28
AU1727702A (en) 2002-07-01
EP1363925B8 (de) 2007-04-25
US20060211636A1 (en) 2006-09-21
HUP0302526A2 (hu) 2003-11-28
PL365012A1 (en) 2004-12-27
DE60124594T2 (de) 2007-10-04
EP1363925B1 (de) 2006-11-15
JP2004531471A (ja) 2004-10-14
ES2275621T3 (es) 2007-06-16
KR20030068189A (ko) 2003-08-19
CZ20031751A3 (cs) 2004-03-17

Similar Documents

Publication Publication Date Title
DE60124594D1 (de) Makrolidantibiotika
DE60003586D1 (de) Antibiotische azalid-zusammensetzungen
CY20162200001T2 (el) Αντιιικοι παραγοντες
DE69913738D1 (de) Ketolid-antibiotika
IS5528A (is) Ný makrólíð
AU2002217277A1 (en) Macrolide antibiotics
MXPA03001148A (es) Antibioticos macrolidos.
PT1303521E (pt) Derivados de tetra-hidro-heterocicloazepinil-pirimidina
IS5919A (is) Ný makrólíð sýklalyf
DE69838651D1 (de) Erythromycinderivate
NO20014362L (no) Erytromycinderivater
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
AR028602A1 (es) Derivados de pirrol
DE60102936D1 (de) Antibakterielle mutiline
AR028282A1 (es) Derivados de aminofenil pirimidona
PT1322593E (pt) Derivados o-substituidos de 6-metiltramadol
PT1317179E (pt) Formulacoes de mesotriona
PT1246791E (pt) Derivados de aminometilfenilciclo-hexanona
ATE440591T1 (de) Ionophore antibiotische formulierungen
FR2814511B1 (fr) Structure de portail
DE50112620D1 (de) Anschlagpuffer
NO20016200D0 (no) Antibiotika
EP1201677A4 (de) Neuartiges makrolid
DK1212337T3 (da) Pesticidmakrolider
HK1062443A (en) Macrolide antibiotics

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties